To this end, leukemic cells derived from different CLL patients were incubated with BAFF in the presence or absence of belimumab or control antibody and exposed to idelalisib, ibrutinib and venetoclax. This evidence concerns the gene TNFSF13B and B-cell chronic lymphocytic leukemia.